Abattis Bioceuticals Corp. (ATTBF)
For informational purposes only. Not financial advice. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Abattis Bioceuticals Corp. (ATTBF) with AI Score 64/100 (Hold). Abattis Bioceuticals Corp. is a Canadian life sciences company focused on developing and licensing natural health products and cannabinoid-enhanced nutraceuticals. Market cap: 0, Sector: Healthcare.
Last analyzed: Mar 16, 2026Abattis Bioceuticals Corp. (ATTBF) Healthcare & Pipeline Overview
Abattis Bioceuticals Corp., based in Canada, develops and licenses natural health products, medicines, and cannabinoid-enhanced nutraceuticals for the biological, nutraceutical, bioceutical, and cosmetic markets. The company also provides Health-Canada licensed services for the cannabis industry, operating in a competitive and evolving healthcare landscape.
Investment Thesis
Investing in Abattis Bioceuticals Corp. presents a high-risk, high-reward scenario. The company operates in the volatile and competitive healthcare sector, specifically targeting the nutraceutical and cannabis markets. A potential value driver is the increasing acceptance and legalization of cannabis in various jurisdictions, which could boost demand for Abattis' cannabinoid-enhanced products and services. However, the company's negative P/E ratio of -0.01 and a significantly negative profit margin of -852.4% indicate substantial financial challenges. The company's high gross margin of 67.6% suggests potential profitability if operational efficiencies improve. The beta of -46.51 indicates an inverse correlation with the market, which may offer diversification benefits but also reflects underlying instability. Success hinges on Abattis' ability to secure funding, expand its market reach, and achieve profitability in a rapidly evolving regulatory environment. Investors should carefully consider the risks associated with OTC-listed companies and the inherent uncertainties of the biotechnology sector.
Based on FMP financials and quantitative analysis
Key Highlights
- Gross Margin of 67.6% indicates potential for profitability if operational costs are managed effectively.
- Negative Profit Margin of -852.4% reflects significant financial challenges and operational inefficiencies.
- Market Cap of $0.00B signifies the company's small size and limited market capitalization.
- P/E Ratio of -0.01 indicates the company is currently not profitable.
- Beta of -46.51 suggests the stock price moves inversely to the market, but also indicates high volatility and potential instability.
Competitors & Peers
Strengths
- Diversified product range in natural health and cannabinoid-enhanced nutraceuticals.
- Health-Canada licenses for cannabis industry services.
- Proprietary formulations and expertise in natural health product development.
- Established presence in the Canadian market.
Weaknesses
- Negative profit margins and financial instability.
- Limited market capitalization and brand recognition.
- Dependence on regulatory approvals for cannabis-related products.
- Competition from larger and more established players.
Catalysts
- Upcoming: Potential regulatory approvals for new cannabinoid-based products.
- Ongoing: Expansion of distribution network within Canada.
- Ongoing: Development of new natural health products.
- Ongoing: Strategic partnerships and acquisitions to expand product portfolio.
- Ongoing: Increased consumer demand for natural health solutions.
Risks
- Potential: Regulatory changes affecting the cannabis and natural health product industries.
- Ongoing: Intense competition from established pharmaceutical and nutraceutical companies.
- Potential: Product recalls or safety concerns.
- Ongoing: Negative profit margins and financial instability.
- Potential: Economic downturn affecting consumer spending on health and wellness products.
Growth Opportunities
- Expansion of Cannabinoid-Enhanced Product Line: The increasing acceptance and legalization of cannabis offer a significant growth opportunity for Abattis. By expanding its 'Comfort' product line and developing new cannabinoid-enhanced nutraceuticals, Abattis can capitalize on the growing demand for cannabis-based health and wellness products. The global cannabis market is projected to reach $90.4 billion by 2026, providing a substantial market for Abattis to target. Success depends on navigating regulatory hurdles and effectively marketing its products to health-conscious consumers. Timeline: Ongoing.
- Geographic Expansion within Canada: Abattis can pursue growth by expanding its distribution network and market presence across Canada. As different provinces implement their cannabis regulations, Abattis can strategically enter new markets and establish partnerships with retailers and distributors. This expansion can increase brand visibility and drive sales growth. The Canadian cannabis market is expected to continue its growth trajectory, offering a favorable environment for Abattis to expand its geographic footprint. Timeline: Ongoing.
- Development of New Natural Health Products: Abattis can invest in research and development to create new natural health products targeting specific health conditions and consumer needs. By leveraging its expertise in natural ingredients and formulations, Abattis can develop differentiated products that appeal to health-conscious consumers. The global natural health products market is expected to grow, driven by increasing consumer awareness of preventive healthcare and the benefits of natural remedies. Timeline: Ongoing.
- Strategic Partnerships and Acquisitions: Abattis can pursue strategic partnerships and acquisitions to expand its product portfolio, market reach, and technological capabilities. Collaborating with other companies in the natural health and cannabis industries can provide access to new markets, technologies, and expertise. Strategic acquisitions can add complementary products and services to Abattis' portfolio, accelerating growth and enhancing its competitive position. Timeline: Ongoing.
- Expansion of Health-Canada Licensed Services for the Cannabis Industry: Abattis can grow its service offerings to cannabis companies, providing Health-Canada licensed services such as testing, research, and regulatory compliance support. As the cannabis industry matures, there is increasing demand for specialized services to ensure product quality, safety, and regulatory compliance. By expanding its service capabilities, Abattis can generate revenue from cannabis companies and establish itself as a trusted service provider in the industry. Timeline: Ongoing.
Opportunities
- Expansion into new geographic markets within Canada and internationally.
- Development of new natural health products targeting specific health conditions.
- Strategic partnerships and acquisitions to expand product portfolio and market reach.
- Increased demand for cannabinoid-based therapies and natural health solutions.
Threats
- Evolving regulatory landscape for cannabis and natural health products.
- Intense competition from established pharmaceutical and nutraceutical companies.
- Potential for product recalls or safety concerns.
- Economic downturn affecting consumer spending on health and wellness products.
Competitive Advantages
- Proprietary formulations for natural health products.
- Health-Canada licenses for providing services to the cannabis industry.
- Brand recognition for its 'Comfort' cannabinoid-enhanced nutraceutical.
- Expertise in developing and commercializing natural health products.
About ATTBF
Abattis Bioceuticals Corp., incorporated in 1997 and headquartered in Vancouver, Canada, operates as a life sciences and biotechnology company. Originally named Abattis Biologix Corporation, the company rebranded in September 2012 to reflect its focus on bioceuticals. The company develops and licenses a range of natural health products, medicines, extractions, and ingredients, targeting the biological, nutraceutical, bioceutical, and cosmetic sectors. Its product portfolio includes 'Comfort,' a cannabinoid-enhanced nutraceutical designed for pain and inflammation relief. Abattis also offers Health-Canada licensed services to businesses operating within the cannabis industry, positioning itself as a service provider in this emerging market. The company's strategy involves developing and commercializing innovative health and wellness products, leveraging natural ingredients and cannabinoid science. Abattis aims to capitalize on the growing demand for natural health solutions and the expanding cannabis market in Canada.
What They Do
- Develops and licenses natural health products.
- Creates medicines for various health conditions.
- Produces extractions and ingredients for biological applications.
- Offers nutraceutical products for health and wellness.
- Formulates bioceutical products.
- Develops cosmetic products.
- Provides 'Comfort,' a cannabinoid-enhanced nutraceutical for pain and inflammation.
- Offers Health-Canada licensed services for the cannabis industry.
Business Model
- Develops and licenses natural health product formulations.
- Generates revenue through the sale of its 'Comfort' cannabinoid-enhanced nutraceutical.
- Provides Health-Canada licensed services to cannabis companies, generating service fees.
- Commercializes its products through distribution agreements and direct sales.
Industry Context
Abattis Bioceuticals Corp. operates within the specialty and generic drug manufacturing industry, a segment of the broader healthcare sector. This industry is characterized by intense competition, evolving regulatory landscapes, and increasing demand for innovative and natural health solutions. The global nutraceutical market is projected to reach $441.7 billion by 2026, driven by growing consumer awareness of preventive healthcare and the benefits of natural ingredients. The cannabis market, particularly in Canada, presents another significant opportunity, with increasing legalization and acceptance driving growth. Abattis competes with other companies developing and marketing natural health products and cannabinoid-based therapies. Success in this environment requires strong product differentiation, regulatory compliance, and effective marketing strategies.
Key Customers
- Consumers seeking natural health solutions.
- Patients looking for pain and inflammation relief.
- Companies in the cannabis industry requiring Health-Canada licensed services.
- Businesses in the biological, nutraceutical, bioceutical, and cosmetic markets.
Financials
Chart & Info
Abattis Bioceuticals Corp. (ATTBF) stock price: Price data unavailable
Latest News
No recent news available for ATTBF.
Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for ATTBF.
Price Targets
Wall Street price target analysis for ATTBF.
MoonshotScore
What does this score mean?
The MoonshotScore rates ATTBF's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Francesco Paolini
CEO
Francesco Paolini serves as the CEO of Abattis Bioceuticals Corp. His background includes experience in the biotechnology and life sciences sectors. He has been involved in various aspects of company management, including strategic planning, product development, and business development. His expertise lies in navigating the regulatory landscape and commercializing innovative health and wellness products. He is focused on driving growth and creating value for shareholders.
Track Record: Under Francesco Paolini's leadership, Abattis Bioceuticals Corp. has focused on developing and licensing natural health products and cannabinoid-enhanced nutraceuticals. Key milestones include the development of the 'Comfort' product line and the expansion of Health-Canada licensed services for the cannabis industry. He has been instrumental in guiding the company through the evolving regulatory environment and positioning it for growth in the natural health and cannabis markets.
ATTBF OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Abattis Bioceuticals Corp. may not meet the minimum financial standards required for higher tiers like OTCQX or OTCQB. Companies in this tier often have limited financial disclosure, and may not be current in their reporting requirements. Investing in companies on the OTC Other tier carries significant risks due to the lack of transparency and regulatory oversight compared to companies listed on major exchanges like the NYSE or NASDAQ. Investors should exercise extreme caution and conduct thorough due diligence before considering an investment in ATTBF.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited financial disclosure and transparency.
- Higher risk of fraud or manipulation due to less regulatory oversight.
- Significant price volatility due to low trading volumes.
- Potential for delisting or trading suspensions.
- Difficulty in obtaining accurate and timely information about the company.
- Verify the company's registration and legal standing.
- Review available financial statements and disclosures.
- Assess the company's business model and competitive landscape.
- Evaluate the management team and their track record.
- Understand the risks associated with the OTC Other tier.
- Consult with a financial advisor before investing.
- Monitor news and announcements related to the company.
- Health-Canada licenses for cannabis industry services.
- Development of the 'Comfort' cannabinoid-enhanced nutraceutical.
- Established presence in the Canadian market.
- Company has been in operation since 1997.
Abattis Bioceuticals Corp. Stock: Key Questions Answered
What does Abattis Bioceuticals Corp. do?
Abattis Bioceuticals Corp. is a Canadian life sciences company that develops and licenses natural health products, medicines, extractions, and ingredients for the biological, nutraceutical, bioceutical, and cosmetic markets. The company also provides Health-Canada licensed services for the cannabis industry. Its key product is 'Comfort,' a cannabinoid-enhanced nutraceutical for pain and inflammation. The company operates in a competitive healthcare landscape, focusing on the development and commercialization of innovative health and wellness solutions.
What are the key growth opportunities for ATTBF in healthcare?
Abattis Bioceuticals Corp. can expand its market reach by introducing new therapeutic areas, geographic markets, or healthcare segments. The company can also focus on developing new natural health products targeting specific health conditions and consumer needs. Strategic partnerships and acquisitions can provide access to new markets, technologies, and expertise. The increasing acceptance and legalization of cannabis offer a significant growth opportunity for Abattis' cannabinoid-enhanced products and services.
What is Abattis Bioceuticals Corp.'s drug pipeline status?
Abattis Bioceuticals Corp. focuses on developing and licensing natural health products and cannabinoid-enhanced nutraceuticals rather than traditional pharmaceuticals. The company's key product is 'Comfort,' a cannabinoid-enhanced nutraceutical for pain and inflammation. While Abattis may not have a traditional drug pipeline, it continuously explores new formulations and applications for its natural health products and cannabinoid-based therapies. The company's success depends on navigating regulatory hurdles and effectively marketing its products to health-conscious consumers.
What are the main risks for ATTBF?
Abattis Bioceuticals Corp. faces several risks, including regulatory changes affecting the cannabis and natural health product industries, intense competition from established pharmaceutical and nutraceutical companies, and potential product recalls or safety concerns. The company's negative profit margins and financial instability pose significant challenges. An economic downturn could also affect consumer spending on health and wellness products. As an OTC-listed company, ATTBF faces additional risks related to limited financial disclosure, price volatility, and potential for fraud or manipulation.
How does Abattis Bioceuticals Corp. compete in the nutraceutical market?
Abattis Bioceuticals Corp. competes in the nutraceutical market by developing and licensing natural health products and cannabinoid-enhanced nutraceuticals. The company differentiates itself through its expertise in natural ingredients and formulations, as well as its focus on the cannabis industry. Abattis' 'Comfort' product line targets the growing demand for pain and inflammation relief. The company's success depends on its ability to develop innovative products, navigate regulatory hurdles, and effectively market its products to health-conscious consumers.
What are the key factors to evaluate for ATTBF?
Abattis Bioceuticals Corp. (ATTBF) currently holds an AI score of 64/100, indicating moderate score. Key strength: Diversified product range in natural health and cannabinoid-enhanced nutraceuticals.. Primary risk to monitor: Potential: Regulatory changes affecting the cannabis and natural health product industries.. This is not financial advice.
How frequently does ATTBF data refresh on this page?
ATTBF prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven ATTBF's recent stock price performance?
Recent price movement in Abattis Bioceuticals Corp. (ATTBF) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Diversified product range in natural health and cannabinoid-enhanced nutraceuticals.. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Financial data may be outdated or incomplete due to the company's OTC listing and disclosure status.
- AI analysis pending for ATTBF.